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Abstract Mutations in the murine Pax-3 gene lead to a range of
developmental abnormalities including deficiencies in sensory and
sympathetic neurones. We have investigated Pax-3 expression
during neuronal differentiation and show levels of Pax-3 DNA
binding decrease upon cell cycle arrest and morphological
differentiation. The fall in Pax-3 DNA binding occurs within
1 h of the induction of differentiation and is mediated in part by a
decrease in Pax-3 mRNA. This decrease in Pax-3 binding
activity precedes any changes in cell proliferation or morphology,
suggesting that the downregulation of this transcription factor
may be an important prerequisite for the differentiation of
neuronal progenitor cells.
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1. Introduction
Pax-3 is a member of a family of evolutionarily conserved
transcription factors, which share a conserved DNA binding
motif of 128 amino acids, known as the paired-box motif
[1,2]. In mice, nine paired-box encoding genes have so far
been identi¢ed, and these have been named Pax-1 to Pax-9
[3]. The importance of this gene family in embryogenesis has
been demonstrated by the ¢nding that speci¢c mutations with-
in a number of the Pax genes lead to a range of developmen-
tal abnormalities in both humans and mice. Mutations in the
PAX-6 gene lead to the human genetic disorder aniridia [4,5]
and the small eye phenotype in mice [6]. The Pax-1 gene is
mutated in undulated mice [7] and disruption of the PAX-3
gene results in the Waardenburg syndrome in humans [8^10]
and the splotch phenotype in mice [11,12]. Homozygous
splotch mice die in utero on embryonic day 14 (E14), and
display severe neural tube defects, a lack of musculature
and de¢ciencies in neural crest-derived cell types such as
Schwann cells, sensory and sympathetic neurones.
Analysis of Pax-3 expression has revealed that it is ex-
pressed in a temporally and spatially restricted manner during
embryogenesis [13]. Expression of Pax-3 is ¢rst detected in
day 8.5 mouse embryos within the developing spinal cord
and brain. Expression of Pax-3 is also observed within the
neural crest, a transient embryonic stem cell population which
upon di¡erentiation gives rise to a multitude of cell types
including Schwann cells and sensory and sympathetic neuro-
nes of the peripheral nervous system. During Schwann cell
development Pax-3 expression is limited to Schwann cell pre-
cursors or embryonic Schwann cells [14]. No expression of
Pax-3 is detected after the terminal di¡erentiation of these
cells into non-proliferative myelinating Schwann cells. Within
the Schwann cell lineage the restriction of Pax-3 transcripts to
immature Schwann cells has led to the hypothesis that Pax-3
may play an important role during the di¡erentiation of
Schwann cells by establishing and maintaining the phenotype
of pre- di¡erentiated Schwann cells prior to their terminal
di¡erentiation.
To determine whether Pax-3 may also be involved in the
di¡erentiation of neuronal cells, we have studied the expres-
sion and regulation of Pax-3 in the neuronal cell line ND7
[15]. ND7 cells normally proliferate inde¢nitely in the pres-
ence of 10% serum, but upon the addition of 1 mM cyclic
AMP/0.1% serum undergo cell cycle arrest and morphological
di¡erentiation. The di¡erentiated cells produce long neurite
processes, secrete sensory neuropeptides such as the calcitonin
gene-related peptide, and exhibit electrophysiological re-
sponses to bradykinin, all properties characteristic of a mature
sensory neurone. In this study, we report that high levels of
Pax-3 binding activity are associated with mitotically active
immature neuronal cells. Within 1 h of the induction of di¡er-
entiation, we found that the DNA binding activity of Pax-3
was rapidly downregulated, prior to any overt changes in cell
morphology or cell proliferation.
2. Materials and methods
2.1. Cell culture
ND7 cells were grown in Leibovitz’s 15 medium (L15) containing
10% bovine calf serum and either maintained in this medium or trans-
ferred to L15 medium containing 1 mM dibutyryl cyclic AMP and
0.1% serum.
2.2. Electrophoretic mobility shift assays
Oligonucleotides for use in electrophoretic mobility shift assays
were annealed by heating to 85‡C for 3 min and labelled using
[Q-32P]ATP and polynucleotide kinase (Promega). The oligonucleoti-
des used were the e5 oligonucleotide [16] (5P-CTCAGCACCGCAC-
GATTAGCACCGTTCCGCTTC-3P) and the DNA binding site for
the Sp1 general transcription factor 5P-ATTCGATCGGGGCGGGG-
CGAGC-3P. Nuclear extracts were made using the method described
by Dignam et al. [17] and electrophoretic mobility shift assays carried
out as previously described [18]. Competitions were performed using
100-fold excess of unlabelled oligonucleotide which was incubated
with the nuclear extracts prior to the addition of the probe. To con-
¢rm the identity of the retarded complex, nuclear extracts were also
incubated on ice for 15 min with 4 Wl of 1 Wg/ml speci¢c antiserum
prior to the addition of the probe.
2.3. Antibodies
Anti-Pax-3 antiserum was made against a polypeptide containing
amino acids 280^479 of Pax-3. This antibody has been shown to
speci¢cally recognise Pax-3 [19] and in Western blotting experiments
the antibody recognises only one protein in ND7 cells which has a
molecular weight of 56 kDa, the estimated molecular weight for Pax-3
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(data not shown). Anti-Pax-5 and Brn3b antibodies were obtained
from Santa Cruz.
2.4. RT-PCR
Total cellular RNA was extracted using Trizol (Gibco) and used as
a template to prepare complementary DNA (cDNA) using Moloney
murine leukaemia virus reverse transcriptase (MoMLV RT) (Gibco).
RNA concentrations were determined by slot-blot hybridisations. The
cDNA was then ampli¢ed using Taq polymerase (Promega) with spe-
ci¢c primers for Pax-3 and cyclophilin [20]. The PCR conditions in
which the input cDNA was linearly proportional to the PCR product
were initially established for each primer pair by taking aliquots at 15,
20, 25, 30 and 35 cycles to locate the exponential phase of the PCR
cycle. On the basis of these initial experiments, one tenth of the cDNA
sample was ampli¢ed for 25 cycles with the Pax-3 primers and 20
cycles with the cyclophilin primers. Samples were analysed on 2%
agarose gels, followed by Southern blotting and hybridisation with
radiolabelled probes. The PCR primers used for the cyclophilin
PCR were (a) 5P-TTGGGTCGCGTCTGCTTCGA-3P, (b) 5P-GC-
CAGGACCTGTATGCTTCA-3P and for Pax-3 (a) 5P-GGAATA-
CAAAGAGAGAACCCG-3P, (b) 5P-CTTCATCTCACTGAGGTG-
CG-3P.
2.5. Cell proliferation studies
ND7 cells were plated onto 9 cm dishes in medium containing 10%
serum at a density of 5U105 cells per dish. The medium was replaced
with 0.1% serum/1 mM cyclic AMP for 1, 2, 6, 24, 48 and 72 h. 1 WCi
of [3H]methylthymidine (1 mCi/ml, Amersham) was added to each of
the dishes for the last hour of incubation. The cells were then washed
twice with 1 ml phosphate bu¡ered saline (PBS) and harvested by
scraping into 62.5 mM Tris-HCl pH 7.5. Triplicate aliquots were
then precipitated with ice-cold 10% trichloroacetic acid (TCA). After
30 min at 0‡C, the precipitates were diluted with 0.5 ml of TCA and
collected onto G/C ¢lters (Whatman). The ¢lters were then washed
with 10% TCA, dried and counted in optiphase Hi-safe 3 scintillant
(Fisons). Values shown represent the average relative amounts of
tritiated thymidine incorporation in triplicate cultures of 0.1% se-
rum/1 mM cyclic AMP-treated cells compared to triplicate control
cultures of proliferating ND7 cells.
2.6. Neurite outgrowth
Neurite outgrowth was determined by counting the number of
processes greater than 20 Wm in length. The number of cells exhibiting
outgrowths is expressed as a percentage of the total number of cells.
3. Results and discussion
3.1. Pax-3 DNA binding activity in proliferating neuronal cells
To determine the role that Pax-3 plays in neuronal cell
development, we have studied the DNA binding activity of
this transcription factor in a series of proliferating neuronal
cell lines. The DNA binding activity of Pax-3 was analysed by
electrophoretic mobility shift assay (EMSA), in which nuclear
extracts from the di¡erent cell lines were incubated with a
radiolabelled oligonucleotide containing the e5 sequence.
The e5 sequence contains a high a⁄nity binding site for
Pax-3, which is derived from the Drosophila even skipped pro-
moter [16]. As shown in Fig. 1A, one major e5 binding protein
was observed in extracts made from proliferating ND7 cells.
The binding of this protein was sequence-speci¢c, since bind-
ing was abolished by competition with an excess of unlabelled
e5 oligonucleotide but not by competition with an excess of
unlabelled oligonucleotide containing the binding site for the
general transcription factor Sp1. Furthermore, the identity of
this e5 binding protein as Pax-3 was con¢rmed by the addi-
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Fig. 1. A: EMSA using the e5 oligonucleotide with nuclear extracts
from proliferating ND7 cells alone (track 1), in the presence of one
hundred fold excess of unlabelled Sp1 oligonucleotide (track 2), and
in the presence of 100-fold excess of unlabelled e5 oligonucleotide
(track 3). B: EMSA with the e5 oligonucleotide with nuclear ex-
tracts from proliferating ND7 cells alone (track 1), or in the pres-
ence of preimmune serum (track 2), anti-Pax-3 antiserum (track 3),
Pax-5 antibody (track 4) and Brn3b antibody (track 5). C: EMSA
with the e5 oligonucleotide with nuclear extracts from proliferating
ND7 cells (track 1), PC12 cells (track 2), ND7 cells grown in 0.1%
serum/1 mM cyclic AMP (track 3), PC12 cells in the presence of
5 ng/ml NGF (track 4) and N18 cells (track 5).
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tion of Pax-3-speci¢c antibody, which abolished binding (Fig.
1B) [19]. No e¡ect on binding was observed by preincubation
with antibodies raised either against Pax-5, another member
of this developmental gene family, or against the homeodo-
main transcription factor Brn3b (Fig. 1B).
High levels of Pax-3 DNA binding activity were found not
only in proliferating ND7 cells, but also in nuclear extracts
made from dividing N18 cells, a mouse neuroblastoma cell
line, and from mitotically active PC12 cells, an adrenal me-
dulla phaeochromocytoma cell line (Fig. 1C). In contrast,
Pax-3 binding activity could not be detected in ND7 cells
grown in the presence of 1 mM cyclic AMP/0.1% serum,
which induces both a cessation in cell proliferation and mor-
phological di¡erentiation. The DNA binding activity of Pax-3
was also downregulated upon PC12 di¡erentiation. Within 72
h of the addition of 5 ng/ml nerve growth factor (NGF),
which induces both the morphological di¡erentiation of the
PC12 cells into a mature sympathetic neurone-like phenotype
and a cessation in cell proliferation, we found that the DNA
binding activity of Pax-3 had declined to undetectable levels
(Fig. 1C). Thus Pax-3 binding activity in vitro appears to be
restricted to mitotically active immature neuronal cells of both
sensory and sympathetic lineages.
3.2. The DNA binding activity of Pax-3 is rapidly
downregulated upon ND7 di¡erentiation
To analyse what role Pax-3 may play in the di¡erentiation
of neuronal cells, we set up a time course experiment to in-
vestigate the kinetics of the decrease in Pax-3 DNA binding
activity. To do this, ND7 cells were grown either in 10%
serum or transferred to medium containing 1 mM cyclic
AMP/0.1% serum for 1, 6 and 72 h. At each of these time
points, nuclear extracts were made and incubated with the e5
oligonucleotide. As shown in Fig. 2, upon the addition of
di¡erentiation medium, the DNA binding activity of Pax-3
fell rapidly. Within 1 h of the addition of cyclic AMP/0.1%
serum, the DNA binding activity of Pax-3 had fallen to un-
detectable levels despite long exposures of the EMSA to X-ray
¢lm.
Having shown that the DNA binding activity of Pax-3 is
rapidly downregulated upon di¡erentiation, we also wished to
establish whether the fall in Pax-3 binding activity was mir-
rored by a similar decrease in the level of Pax-3 mRNA ex-
pression. To achieve this, RNA was isolated from both pro-
liferating ND7 cells and from cells grown for 1, 2, 6 or 24 h in
1 mM cyclic AMP/0.1% serum. The RNA from each of these
time points was then used as a template for cDNA synthesis
and ampli¢ed using quantitative PCR with primers speci¢c for
Pax-3 and the housekeeping gene cyclophilin. We found, as
shown in Fig. 3, high levels of Pax-3 mRNA in proliferating
ND7 cells. Interestingly, unlike the DNA binding activity of
Pax-3 which was downregulated within 1 h, no change in Pax-
3 mRNA levels was initially observed within 1 h of the addi-
tion of di¡erentiation medium. However, 2^6 h after the in-
duction of di¡erentiation, Pax-3 mRNA levels did fall dra-
matically to very low levels. The levels of cyclophilin remained
unchanged. These results show that at least in part the down-
regulation in Pax-3 binding activity is mediated by a decrease
in Pax-3 mRNA expression, although the initial fall in Pax-3
binding activity may be mediated by post-transcriptional
changes in either Pax-3 expression or binding activity.
3.3. The role of Pax-3 in ND7 di¡erentiation
To analyse what role the rapid downregulation in Pax-3
activity plays in the di¡erentiation of neuronal cells, we
wished to determine how the decline in the DNA binding
activity of Pax-3 correlated with the appearance of overt signs
of morphological di¡erentiation and/or the onset of cell cycle
arrest, which accompanies morphological di¡erentiation. The
degree of morphological di¡erentiation, judged by counting
the percentage of cells bearing neurite outgrowths, and the
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Fig. 3. RT-PCR showing a decrease in the level of Pax-3 mRNA
upon di¡erentiation. cDNA was prepared from ND7 cells grown in
10% serum or grown in 0.1% serum/1 mM cyclic AMP for 1, 2 or
6 h.
Fig. 2. EMSA showing the decrease in Pax-3 binding activity upon
ND7 cell di¡erentiation. The e5 oligonucleotide was incubated with
nuclear extracts from ND7 cells grown in 10% serum, or with ex-
tracts made from ND7 cells incubated in 0.1% serum/1 mM cyclic
AMP for 1, 6 or 72 h.
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rate of cell proliferation, measured by incorporation of triti-
ated thymidine, was analysed and compared with changes
observed in the binding activity of Pax-3 upon addition of
di¡erentiation medium. We found, as shown in Fig. 4, that
the fall in the DNA binding activity of Pax-3 occurs prior to
any overt signs of morphological di¡erentiation, and prior to
any detectable changes in the rate of cell proliferation. This
argues that the downregulation of this transcription factor is
not merely a consequence of di¡erentiation but may instead
be a necessary requirement for either the production of a
morphologically mature neurone or for the onset of cell cycle
arrest which accompanies morphological di¡erentiation.
Therefore, to determine whether the fall in Pax-3 binding
activity is involved in the morphological di¡erentiation of
the cells rather than in the onset of cell cycle arrest, we treated
ND7 cells with 1 mM cyclic AMP in the presence of 10%
serum, which induces morphological di¡erentiation without
a cessation in cell proliferation [21]. Under these conditions,
the DNA binding activity of Pax-3 fell within 1 h of the
addition of 1 mM cyclic AMP (Fig. 5). This suggests that
the decrease in the activity of this transcription factor is
closely associated with the production of a morphologically
mature neurone, and raises the possibility that the downregu-
lation in Pax-3 activity may be an important regulatory event
in the morphological di¡erentiation of neuronal cells.
The data in this report therefore suggest that one function
of Pax-3 in immature neuronal cells is to maintain the undif-
ferentiated phenotype of these progenitor cells until appropri-
ate environmental cues signal a downregulation in Pax-3 ac-
tivity and the production of a morphologically mature
neurone. Cyclic AMP may itself play an important neurotro-
phic role in the development of the peripheral nervous system.
Rydel and Green have shown that cyclic AMP analogues
promote neurite outgrowth and cell survival in primary cul-
tures of both sensory and sympathetic neurones [22]. This
cyclic AMP neurotrophic pathway is mediated by the activa-
tion of cyclic AMP-dependent protein kinases and is inde-
pendent of NGF. One possible downstream target for this
cyclic AMP pathway may therefore be the transcriptional reg-
ulator Pax-3 whose downregulation may be important for
either the activation of genes involved in the structure and
function of the mature neurone or the repression of genes
important in the maintenance of the immature phenotype.
Interestingly, Kioussi et al. [14] have also shown that Pax-3
expression is controlled by intracellular cyclic AMP levels.
Treatment of Schwann cells in culture with forskolin, an ago-
nist of cyclic AMP, leads to the repression of Pax-3 RNA
expression and the activation of myelin basic protein, a gene
whose expression is inhibited in the presence of Pax-3. It will
now be important in order to gain further insights into the
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Fig. 5. EMSA with nuclear extracts from proliferating ND7 cells
(ND7) and from ND7 cells incubated for 1 h in growth medium
containing 1 mM cyclic AMP.
Fig. 4. A: Time course of the decline in Pax-3 DNA binding activ-
ity (F), measured by EMSA, and the decline in cellular DNA repli-
cation (R), measured by incorporation of tritiated thymidine upon
addition of 0.1% serum/1 mM cyclic AMP. The DNA binding activ-
ity and incorporation of thymidine are expressed as a percentage of
the value observed in proliferating cells. B: Time course of the de-
cline in Pax-3 DNA binding activity (F) and the increase in neurite
outgrowth (R) upon addition of 0.1% serum/1 mM cyclic AMP.
Neurite outgrowth is expressed as the number of cells exhibiting
neurites longer than 20 Wm as a percentage of the total number of
cells.
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role of Pax-3 in neuronal cell development to begin to identify
some of the target genes regulated by Pax-3 during neuronal
cell di¡erentiation.
Acknowledgements: F.C.R. is supported by the BBSRC. W.J.F. is
supported by the Wistar Institute Cancer Training Grant CA09171.
F.J.R. is supported by NIH Grants CA52009, Core Grant CA10815,
DK49210, GM54220, DAMD17-96-1-6141, and the Irving A. Hansen
Memorial Foundation, the Mary A. Rumsey Memorial Foundation
and the Pew Scholars Program in the Biomedical Sciences.
References
[1] Noll, M. (1993) Curr. Opin. Genet. Dev. 3, 595^605.
[2] Treisman, J., Harris, E. and Desplan, C. (1991) Genes Dev. 5,
594^604.
[3] Deutsch, U. and Gruss, P. (1991) Semin. Dev. Biol. 2, 413^424.
[4] Glaser, T., Lane, J. and Housman, D. (1990) Science 250, 823^
827.
[5] Van Der Meer-De Jong, R., Dickinson, M.E., Woychik, R.P.,
Stubbs, L., Hethrington, C. and Hogan, B.L. (1990) Genomics 7,
270^275.
[6] Hogan, B.L.M., Horsburgh, G., Cohen, J., Hetherington, C.M.,
Fisher, G. and Lyon, M.F. (1986) J. Embryol. Exp. Morphol. 97,
95^100.
[7] Balling, R., Deutsch, U. and Gruss, P. (1988) Cell 55, 531^535.
[8] Foy, C., Newton, V., Wellesly, D., Harris, R. and Read, A.P.
(1990) Am. J. Hum. Genet. 46, 1017^1023.
[9] Baldwin, C.T., Hoth, C.F., Amos, J., Da-Silva, E.O. and Milun-
sky, A. (1990) Nature 355, 637^638.
[10] Tassabehji, M., Read, A.P., Newton, V.E., Harris, R., Balling,
R., Gruss, P. and Strachne, T. (1992) Nature 355, 635^636.
[11] Russell, W.L. (1947) Genetics 32, 107.
[12] Epstein, D.L., Vekemans, M. and Gros, P. (1991) Cell 67, 767^
774.
[13] Goulding, M.D., Chalepakis, G., Deutsch, U., Erselius, J. and
Gruss, P. (1992) EMBO J. 10, 1135^1147.
[14] Kioussi, C., Gross, M.K. and Gruss, P. (1995) Neuron 15, 553^
562.
[15] Wood, J.N., Bevan, S.J., Coote, P.R., Dunn, P., Harmer, A.,
Hogen, P., Latchman, D.S., Morrison, C., Rougeon, G., Theve-
noiu, M. and Wheately, S.C. (1991) Proc. R. Soc. Lond. B 241,
187^198.
[16] Treisman, J., Gonczy, P., Vashintha, M., Harris, E. and Desplan,
C. (1989) Cell 59, 553^562.
[17] Dignam, J.D., Lebovitz, R.M. and Roeder, R.G. (1993) Nucleic
Acids Res. 11, 1471^1489.
[18] Lillycrop, K.A., Dent, C.L., Wheately, S.C., Beech, M.N., Nin-
kina, N.N., Wood, J.N. and Latchman, D.S. (1991) Neuron 7,
381^390.
[19] Fredericks, W.J., Galili, N., Mukhopadhyay, S., Rovera, G.,
Bennicelli, J., Barr, F.G. and Rauscher III, F.J. (1995) Mol.
Cell. Biol. 15, 1522^1535.
[20] Liu, Z., Lillycrop, K.A. and Latchman, D.S. (1995) Neurosci.
Lett. 183, 8^12.
[21] Howard, M.K., Burke, L., Mailhos, C., Pizzey, A., Gilbert, C.S.,
Lawson, D., Collins, M.K.L., Thomas, N.S.B. and Latchman,
D.S. (1993) J. Neurochem. 60, 1783^1791.
[22] Rydel, R.E. and Greene, L.A. (1988) Proc. Natl. Acad. Sci. USA
85, 1257^1261.
FEBS 19746 26-1-98
F.C. Reeves et al./FEBS Letters 422 (1998) 118^122122
